Another Biopharma Firm Halts Sci-Tech Board IPO: Suzhou Ribo Life Science Withdraws Application

Recently, the Shanghai Stock Exchange announced its decision to terminate the review of the initial public offering (IPO) and listing on the Science and Technology Innovation Board (STAR Market) by Suzhou Ribo Life Science Co., Ltd. (hereinafter referred to as "Ribo Life Science").

Prior to this, Ribo Life Science and its sponsor, Guotai Junan Securities Co., Ltd., had already respectively submitted to the Shanghai Stock Exchange the 《Application of Suzhou Ribo Life Science Co., Ltd. for the Withdrawal of Application Documents for the Initial Public Offering and Listing on the Science and Technology Innovation Board》 and the 《Application of Guotai Junan Securities Co., Ltd. for the Withdrawal of Application Documents for the Initial Public Offering and Listing on the Science and Technology Innovation Board of Suzhou Ribo Life Science Co., Ltd.》, applying to withdraw the application documents.

Notably, since January this year, in addition to Suzhou Ribo Life Science, the STAR Market IPOs of Tasly Biologics, Yiteng Jingang, Shanghai Aopu Biotechnology, Beijing Tianguangshi Biotechnology, and Danna Biotechnology have also been terminated.